{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T18:30:22Z","timestamp":1789065022484,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.amjcard.2023.03.025","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T08:37:12Z","timestamp":1682498232000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations"],"prefix":"10.1016","volume":"197","author":[{"given":"Pascal M.","family":"Burger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna D.","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannick A.N.","family":"Dorresteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koudstaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Teraa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"de Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon G.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3951-5223","authenticated-orcid":false,"given":"Frank L.J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2023.03.025_bib0001","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0002","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2018.08.1043","article-title":"Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week","volume":"72","author":"Libby","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0003","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER study","volume":"55","author":"Glynn","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0006","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.106.649939","article-title":"Prognostic significance of the Centers for Disease Control\/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease","volume":"115","author":"Sabatine","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012638","article-title":"hsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study","volume":"8","author":"Carrero","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of atherosclerotic Plaque by Initiation of darapladib Therapy) trial","volume":"6","author":"Held","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0009","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1093\/eurheartj\/ehy633","article-title":"Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions","volume":"39","author":"Kalkman","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0011","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0012","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/2396987320984003","article-title":"Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: systematic review and meta-analysis","volume":"6","author":"McCabe","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0013","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejvs.2017.05.009","article-title":"Systematic review and meta-analysis of the association between C-reactive protein and major cardiovascular events in patients with peripheral artery disease","volume":"54","author":"Singh","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0014","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0016","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0017","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-066952","article-title":"Cohort profile: the Utrecht cardiovascular Cohort-Second Manifestations of arterial Disease (UCC-SMART) Study-an ongoing prospective cohort study of patients at high cardiovascular risk in the Netherlands","volume":"13","author":"Castelijns","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0018","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/01.CIR.0000052939.59093.45","article-title":"Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association","volume":"107","author":"Pearson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0019","first-page":"341","article-title":"Comparison of high-sensitivity C-reactive protein serum assay results obtained using Dade-Behring BNII nephelometer and Ortho vitros FS 5.1 clinical analyzer in respect of CRP-related risk assessment of chronic metabolic diseases","volume":"54","author":"Kusnierz-Cabala","year":"2008","journal-title":"Clin Lab"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1558-5646.1989.tb04220.x","article-title":"Analyzing tables of statistical tests","volume":"43","author":"Rice","year":"1989","journal-title":"Evolution"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0021","unstructured":"NIH U.S. National Library of Medicine, Colchicine and spironolactone in patients with MI \/ SYNERGY stent registry (CLEAR SYNERGY), 2017. Available at: https:\/\/clinicaltrials.gov\/show\/NCT03048825. Accessed on November 7, 2022."},{"key":"10.1016\/j.amjcard.2023.03.025_bib0022","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/2396987320972566","article-title":"Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) - study protocol for a randomised controlled trial","volume":"6","author":"Kelly","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0023","unstructured":"NIH U.S. National Library of Medicine, Low dose ColchicinE in pAtients with peripheral artery Disease to address residual vascular risk (LEADER-PAD), 2021. Available at: https:\/\/clinicaltrials.gov\/show\/NCT04774159. Accessed on November 7, 2022."},{"key":"10.1016\/j.amjcard.2023.03.025_bib0024","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0025","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0026","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0027","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0028","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2023.03.025_bib0029","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1093\/eurheartj\/ehz587","article-title":"The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study","volume":"40","author":"Van't Klooster","year":"2019","journal-title":"Eur Heart J"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914923001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:44Z","timestamp":1762078064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914923001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"alternative-id":["S0002914923001819"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.03.025","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2023.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}